WO2021132077A1 - セサミン類及びpqqを含有する組成物 - Google Patents
セサミン類及びpqqを含有する組成物 Download PDFInfo
- Publication number
- WO2021132077A1 WO2021132077A1 PCT/JP2020/047425 JP2020047425W WO2021132077A1 WO 2021132077 A1 WO2021132077 A1 WO 2021132077A1 JP 2020047425 W JP2020047425 W JP 2020047425W WO 2021132077 A1 WO2021132077 A1 WO 2021132077A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sesamin
- pqq
- composition
- salt
- present
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 141
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 title claims abstract description 139
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 title claims abstract description 138
- VRMHCMWQHAXTOR-CMOCDZPBSA-N sesamin Natural products C1=C2OCOC2=CC([C@@H]2OC[C@@]3(C)[C@H](C=4C=C5OCOC5=CC=4)OC[C@]32C)=C1 VRMHCMWQHAXTOR-CMOCDZPBSA-N 0.000 title claims abstract description 105
- MMXZSJMASHPLLR-UHFFFAOYSA-N pyrroloquinoline quinone Chemical compound C12=C(C(O)=O)C=C(C(O)=O)N=C2C(=O)C(=O)C2=C1NC(C(=O)O)=C2 MMXZSJMASHPLLR-UHFFFAOYSA-N 0.000 claims abstract description 178
- 150000003839 salts Chemical class 0.000 claims abstract description 64
- 230000004898 mitochondrial function Effects 0.000 claims abstract description 48
- 238000004519 manufacturing process Methods 0.000 claims abstract description 31
- 230000002438 mitochondrial effect Effects 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 19
- 235000013305 food Nutrition 0.000 claims description 26
- 230000002929 anti-fatigue Effects 0.000 claims description 22
- 210000003470 mitochondria Anatomy 0.000 claims description 9
- 230000000694 effects Effects 0.000 abstract description 37
- 230000007423 decrease Effects 0.000 abstract description 18
- 230000000052 comparative effect Effects 0.000 description 44
- 206010016256 fatigue Diseases 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 22
- 239000003814 drug Substances 0.000 description 20
- 230000002407 ATP formation Effects 0.000 description 17
- 229940079593 drug Drugs 0.000 description 17
- 238000011084 recovery Methods 0.000 description 16
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 14
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 14
- 230000009471 action Effects 0.000 description 13
- 230000037406 food intake Effects 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 10
- 241000282412 Homo Species 0.000 description 8
- -1 lignan compound Chemical class 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000036284 oxygen consumption Effects 0.000 description 7
- 239000008159 sesame oil Substances 0.000 description 7
- 235000011803 sesame oil Nutrition 0.000 description 7
- 230000037396 body weight Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 241000207961 Sesamum Species 0.000 description 4
- 235000003434 Sesamum indicum Nutrition 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 229940127557 pharmaceutical product Drugs 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229930013686 lignan Natural products 0.000 description 3
- 235000009408 lignans Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 229950006238 nadide Drugs 0.000 description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- MNULEGDCPYONBU-WMBHJXFZSA-N (1r,4s,5e,5'r,6'r,7e,10s,11r,12s,14r,15s,16s,18r,19s,20r,21e,25s,26r,27s,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trio Polymers O([C@@H]1CC[C@@H](/C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H]([C@H]2C)[C@H]1C)CC)[C@]12CC[C@@H](C)[C@@H](C[C@H](C)O)O1 MNULEGDCPYONBU-WMBHJXFZSA-N 0.000 description 2
- MNULEGDCPYONBU-DJRUDOHVSA-N (1s,4r,5z,5'r,6'r,7e,10s,11r,12s,14r,15s,18r,19r,20s,21e,26r,27s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers O([C@H]1CC[C@H](\C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)C(C)C(=O)[C@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)OC([C@H]2C)C1C)CC)[C@]12CC[C@@H](C)[C@@H](CC(C)O)O1 MNULEGDCPYONBU-DJRUDOHVSA-N 0.000 description 2
- MNULEGDCPYONBU-YNZHUHFTSA-N (4Z,18Z,20Z)-22-ethyl-7,11,14,15-tetrahydroxy-6'-(2-hydroxypropyl)-5',6,8,10,12,14,16,28,29-nonamethylspiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2'-oxane]-3,9,13-trione Polymers CC1C(C2C)OC(=O)\C=C/C(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)C\C=C/C=C\C(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-YNZHUHFTSA-N 0.000 description 2
- MNULEGDCPYONBU-VVXVDZGXSA-N (5e,5'r,7e,10s,11r,12s,14s,15r,16r,18r,19s,20r,21e,26r,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers C([C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)OC([C@H]1C)[C@H]2C)\C=C\C=C\C(CC)CCC2OC21CC[C@@H](C)C(C[C@H](C)O)O2 MNULEGDCPYONBU-VVXVDZGXSA-N 0.000 description 2
- MNULEGDCPYONBU-UHFFFAOYSA-N 4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers CC1C(C2C)OC(=O)C=CC(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)CC=CC=CC(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-UHFFFAOYSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- BMZRVOVNUMQTIN-UHFFFAOYSA-N Carbonyl Cyanide para-Trifluoromethoxyphenylhydrazone Chemical compound FC(F)(F)OC1=CC=C(NN=C(C#N)C#N)C=C1 BMZRVOVNUMQTIN-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000019914 Mental Fatigue Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- 241001600434 Plectroglyphidodon lacrymatus Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004065 mitochondrial dysfunction Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229930191479 oligomycin Natural products 0.000 description 2
- MNULEGDCPYONBU-AWJDAWNUSA-N oligomycin A Polymers O([C@H]1CC[C@H](/C=C/C=C/C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)O[C@@H]([C@@H]2C)[C@@H]1C)CC)[C@@]12CC[C@H](C)[C@H](C[C@@H](C)O)O1 MNULEGDCPYONBU-AWJDAWNUSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- XNWFXTOHNKPYMK-UHFFFAOYSA-N 3,3a,4,5,6,6a-hexahydrocyclopenta[c]dioxole Chemical class C1OOC2CCCC21 XNWFXTOHNKPYMK-UHFFFAOYSA-N 0.000 description 1
- 229940126565 ATP-synthase inhibitor Drugs 0.000 description 1
- 244000298697 Actinidia deliciosa Species 0.000 description 1
- 235000009436 Actinidia deliciosa Nutrition 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 240000009164 Petroselinum crispum Species 0.000 description 1
- 241000758706 Piperaceae Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- LUSZGTFNYDARNI-UHFFFAOYSA-N Sesamol Natural products OC1=CC=C2OCOC2=C1 LUSZGTFNYDARNI-UHFFFAOYSA-N 0.000 description 1
- ZZMNWJVJUKMZJY-AFHBHXEDSA-N Sesamolin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3OC2=CC=C3OCOC3=C2)=C1 ZZMNWJVJUKMZJY-AFHBHXEDSA-N 0.000 description 1
- ZZMNWJVJUKMZJY-UHFFFAOYSA-N Sesamolin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3OC2=CC=C3OCOC3=C2)=C1 ZZMNWJVJUKMZJY-UHFFFAOYSA-N 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 241000271567 Struthioniformes Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000013118 diabetic mouse model Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000027721 electron transport chain Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000309715 mini pig Species 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 230000005787 mitochondrial ATP synthesis coupled electron transport Effects 0.000 description 1
- 230000008811 mitochondrial respiratory chain Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 235000013557 nattō Nutrition 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000004108 pentose phosphate pathway Effects 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- JUVIOZPCNVVQFO-UHFFFAOYSA-N rotenone Natural products O1C2=C3CC(C(C)=C)OC3=CC=C2C(=O)C2C1COC1=C2C=C(OC)C(OC)=C1 JUVIOZPCNVVQFO-UHFFFAOYSA-N 0.000 description 1
- 229940080817 rotenone Drugs 0.000 description 1
- KQRXQIPRDKVZPW-UHFFFAOYSA-N sesaminol Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=3OCOC=3C=C2O)=C1 KQRXQIPRDKVZPW-UHFFFAOYSA-N 0.000 description 1
- KQRXQIPRDKVZPW-ISZNXKAUSA-N sesaminol Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=3OCOC=3C=C2O)=C1 KQRXQIPRDKVZPW-ISZNXKAUSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/31—Foods, ingredients or supplements having a functional effect on health having an effect on comfort perception and well-being
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
- C12Y102/99—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with other acceptors (1.2.99)
- C12Y102/99003—Aldehyde dehydrogenase (pyrroloquinoline-quinone) (1.2.99.3)
Definitions
- the present invention relates to compositions containing sesamin and pyrroloquinoline quinone (PQQ).
- the present invention also relates to a method for improving, suppressing or maintaining mitochondrial function and / or mitochondrial energy production ability.
- Energy production refers to producing the energy required to maintain vital activity. Most of the energy production takes place in the mitochondria, one of the organelles in the cell. Nutrient sources such as sugars, lipids, and amino acids ingested from the diet are metabolized by glycolysis, the pentose phosphate pathway, and the citric acid cycle, and converted to NADH (nicotinamide adenine dinucleotide). The NADH electrons are then transferred to the mitochondrial respiratory chain protein (electron transport chain) to produce energy in the form of ATP (adenosine triphosphate). It is known that a decrease in ATP production causes various problems such as obesity due to decreased metabolic capacity, increased risk of developing diabetes, decreased muscle strength, increased fatigue, decreased lethargy / concentration, and depression.
- Maintaining ATP production is important for reducing fatigue, maintaining concentration, exercising with muscles, and maintaining physical and mental vitality.
- Patent Document 1 various energy production-increasing agents containing sugars, amino acids, and lipids, which are substrates necessary for ATP production, have been known.
- Non-Patent Documents 1 and 4 the substrate required for ATP production is converted to ATP via the mitochondrial electron transport chain, but if the substrate increases but the mitochondrial function declines, ATP is produced. It is not possible. It is known that mitochondrial dysfunction is caused by aging and oxidative stress, resulting in a decrease in ATP production (Non-Patent Documents 1 and 4).
- sesamin is a lignan compound contained in sesame and has been reported to have an antioxidant effect. It has been reported that sesamin has an antioxidative effect of suppressing mitochondrial function decline in diabetic model mice (Non-Patent Document 5). Further, it is known that the antioxidant action of sesamin exerts an action of suppressing the production of active oxygen in mitochondria and an action of suppressing a decrease in membrane potential of mitochondria (Non-Patent Document 2). It has also been reported to activate PGC1 ⁇ , which is involved in mitochondrial biosynthesis (Patent Document 2).
- Non-Patent Document 3 pyrroloquinoline quinone
- the present invention provides a highly safe composition that can be used to improve, suppress or maintain mitochondrial function and / or mitochondrial energy production, is easy to take, and can be continuously ingested without fear of side effects.
- the purpose is to provide.
- Another object of the present invention is to provide a method for improving, suppressing or maintaining mitochondrial function and / or mitochondrial energy production ability.
- the present inventors have diligently studied to solve the above problems, and considered that it is effective to exert an effect at a low dose as a means for making it easy to take and continuously ingesting, and mitochondrial function and / or mitochondrial energy production.
- the components that can be used to improve, suppress or maintain the ability were examined.
- sesamines which are components for maintaining and activating mitochondrial function
- PQQ pyrroloquinoline quinone
- sesamine alone or pyrroloquinone or a salt thereof sesamine alone or pyrroloquinone or a salt thereof can be used alone. They have found that they improve, suppress or maintain mitochondrial function and / or mitochondrial energy production more effectively (synergistically) than treatment, and have completed the present invention.
- the present invention relates to the following compositions.
- PQQ pyrroloquinoline quinone
- [10] Selected from the group consisting of "reducing fatigue”, “difficult to feel fatigue”, “maintaining vitality”, “improving vitality”, “helping energy production” and “full of energy”.
- [11] A method for improving, suppressing or maintaining mitochondrial function and / or mitochondrial energy-producing ability by administering one or more of sesamin and pyrroloquinoline quinone (PQQ) or a salt thereof.
- PQQ sesamin and pyrroloquinoline quinone
- a method for suppressing, reducing or ameliorating fatigue by administering one or more of sesamin and pyrroloquinoline quinone (PQQ) or a salt thereof.
- a highly safe composition that can be used to improve, suppress or maintain mitochondrial function and / or mitochondrial energy production ability, is easy to take, and can be continuously ingested without worrying about side effects. Can provide things.
- an effect of continuously improving mitochondrial function and / or mitochondrial energy production ability a decrease suppressing effect or a maintaining effect is exhibited without worrying about side effects, and anti-fatigue. The effect is obtained.
- SE sesamin / episesamin mixture
- PQQ Comparative Examples 5 to 9
- composition of the present invention contains one or more of sesamin.
- Sesamin is one of the main lignan compounds of sesame, and is contained in sesame in an amount of about 0.5 to 1.0% by weight. While long-term ingestion of artificially synthesized compounds is not preferable from the viewpoint of unexpected side effects and the like, sesamins whose safety is guaranteed are most suitable for long-term ingestion.
- sesamin is a general term for compounds containing sesamin and its analogs. Sesamin is one of the major lignan compounds contained in sesame seeds. Examples of sesamin analogs include episesamin and dioxabicyclo [3.3.0] octane derivatives described in JP-A-4-9331. As one or more kinds of sesamin, one kind of these compounds may be used alone, or two or more kinds may be used. Specific examples of sesamin include sesamin, episesamine, sesaminol, episesaminol, sesamol, sesamolin and the like, and these stereoisomers or racemates can be used alone or in combination.
- sesamin and / or episesamin can be preferably used as one or more of the sesamin, and sesamin and episesamin can be more preferably used.
- sesamin and episesamin their ratios are not particularly limited, but for example, sesamin: episesamin (weight ratio) is preferably 1: 0.1 to 1: 9, and more preferably 1: 0.3 to 1: 3. , 1: 0.5 to 1: 2 is more preferable.
- sesamin used in the present invention is not limited by its form, production method, or the like.
- sesamin referred to as sesamin extract or purified product
- a known method for example, the method described in JP-A-4-9331
- commercially available sesame oil (liquid) can be used as it is.
- sesame oil liquid
- the flavor peculiar to sesame oil may be evaluated as sensually unfavorable. Therefore, a tasteless and odorless sesamin extract (or refined sesamin product) extracted from sesame oil is used. Is preferable.
- sesamin when sesame oil is used, the sesamin content is low, and if a preferable amount of sesamin is to be added, the volume of the prescribed composition per unit dose becomes too large, which may cause inconvenience in intake. .. In particular, when the product is formulated for oral administration, the product (tablet, capsule, etc.) becomes too large and the intake is hindered. Therefore, it is preferable to use a sesamin extract (or a purified sesamin product) from sesame oil from the viewpoint that the intake amount may be small. Sesamin can also be obtained by synthesis. As the method, for example, sesamin and episesamin can be synthesized by the method of Beroza et al. (J. Am. Chem. Soc., 78, 1242 (1956)). Metabolites of sesamin and episesamin can be synthesized by the method of Urata et al. (Chem. Pharm. Bull. (Tokyo), 56 (11) 1611-2 (2008)).
- Sesamin is a compound contained in natural products and foods and drinks, which has abundant eating experience and is recognized for its high safety. While long-term ingestion of artificially synthesized compounds is not preferable from the viewpoint of unexpected side effects and the like, sesamins whose safety is guaranteed are most suitable for continuous ingestion and long-term ingestion.
- the composition of the present invention comprises pyrroloquinoline quinone (PQQ) or a salt thereof.
- PQQ is a redox coenzyme. Since PQQ or a salt thereof exists in various organisms such as plants, bacteria, and animals, it can be prepared by extracting from various organisms. Commercially available products can also be used for PQQ or a salt thereof.
- a plant-derived raw material or the like rich in PQQ or a salt thereof may be contained in the composition of the present invention as long as the effects of the present invention are exhibited.
- a salt that can be used for foods and drinks, pharmaceuticals and the like is preferable, and examples thereof include alkali metal salts such as sodium salt and potassium salt; alkaline earth metal salts such as calcium salt and magnesium salt.
- alkali metal salts such as sodium salt and potassium salt
- alkaline earth metal salts such as calcium salt and magnesium salt.
- Specific examples of the PQQ salt include one selected from phosphates such as magnesium, manganese, calcium, sodium, potassium, copper, iron and zinc, hydrochlorides, sulfates and acetates. Two or more types can be used.
- the sodium salt is preferable.
- the number of salt substitutions in the salt of PQQ is 1 to 3, preferably 2.
- the salt of PQQ the disodium salt of PQQ is preferable.
- PQQ is contained in various foods such as fermented foods such as natto, tofu and miso, vegetables such as parsley, peppers and spinach, and fruits such as kiwifruit and papaya. While long-term ingestion of artificially synthesized compounds is not preferable from the viewpoint of unexpected side effects and the like, PQQ whose safety is guaranteed is most suitable for continuous ingestion and long-term ingestion.
- composition containing sesamin and PQQ or a salt thereof contains the above sesamin and the above PQQ or a salt thereof.
- the weight ratio of PQQ to sesamines is PQQ from the viewpoint of synergistically enhancing the mitochondrial function and / or the mitochondrial energy-producing ability improving action, lowering inhibitory action or maintaining action. In terms of conversion, it is preferably 0.01 to 100, more preferably 0.1 to 10, and even more preferably 0.2 to 5.
- the weight ratio of sesamines to PQQ or a salt thereof is used in order to exert an anti-fatigue effect by enhancing mitochondrial function and / or mitochondrial energy production ability improving action, lowering suppressing action or maintaining action. Is preferable from the viewpoint of anti-fatigue action.
- the amount of PQQ or a salt thereof when indicating the amount of PQQ or a salt thereof, the value converted into the amount of pyrroloquinoline quinone (PQQ) is used.
- the composition of the present invention can synergistically enhance the mitochondrial function and / or the mitochondrial energy producing ability improving action, lowering suppressing action or maintaining action. it can.
- the above-mentioned action can be exerted even at a low dose, and a small dose leads to ease of administration, and a composition that is easy to continuously ingest can be obtained. Can be done.
- composition of the present invention can improve, suppress or maintain mitochondrial function.
- composition of the present invention can improve, suppress or maintain the energy-producing ability of mitochondria. Further, as a result, the composition of the present invention exerts an anti-fatigue effect.
- the mitochondrial function and the energy producing ability of mitochondria may be evaluated based on ordinary knowledge in the technical field to which the present invention belongs, and the method thereof is not particularly limited.
- OCR the rate of oxygen consumption used by mitochondria during ATP synthesis in the cell to be measured
- a decoupling agent eg, carbonyl cyanide-p-trifluoromethoxyphenyl hydrazone (FCCP)
- FCCP carbonyl cyanide-p-trifluoromethoxyphenyl hydrazone
- the evaluation items can evaluate mitochondrial function by analyzing, for example, basal respiratory volume, ATP-producing ability, and maximum respiratory volume, which are the main indicators in the evaluation of mitochondrial function.
- composition of the present invention can be an anti-fatigue composition.
- composition of the present invention shall also include an anti-fatigue composition.
- fatigue means a temporary decrease in physical activity ability and mental vitality caused by physical or mental causes. Fatigue is usually accompanied by a feeling of fatigue (eg, discomfort, decreased activity motivation, etc.).
- Anti-fatigue means suppressing, reducing or ameliorating fatigue. Fatigue control includes increasing tolerance to fatigue, preventing fatigue (including reducing risk in subjects at risk of fatigue), and the like. Reducing fatigue includes reducing symptoms of fatigue (eg, feeling tired) and the like. Improvement of fatigue includes recovery from fatigue, improvement of fatigue symptoms, and the like.
- the anti-fatigue composition of the present invention shall be used to suppress, reduce or improve physical fatigue and / or mental fatigue, and to suppress, reduce or improve physical fatigue and / or mental fatigue.
- it can be preferably used to suppress, reduce or improve physical fatigue, and thus to suppress, reduce or improve physical fatigue.
- the composition of the present invention can be in the form of foods and drinks, pharmaceuticals, quasi-drugs, feeds and the like.
- the composition of the present invention is a food or drink, a pharmaceutical product, or a quasi-drug for improving, suppressing or maintaining mitochondrial function, or for improving, suppressing or maintaining mitochondrial energy production ability. , Feed, etc., or materials or formulations used in combination with these.
- the composition of the present invention can be provided, for example, in the form of an agent, but is not limited to this form.
- the agent can be provided as it is as a composition or as a composition containing the agent.
- the anti-fatigue composition of the present invention can also be referred to as an anti-fatigue agent.
- the composition of the present invention may be either an oral composition or a parenteral composition, but is preferably an oral composition.
- oral composition include foods and drinks, oral medicines, quasi-drugs, and feeds, preferably foods and drinks or oral medicines, and more preferably foods and drinks.
- composition of the present invention may contain any additive and any component in addition to one or more of sesamin and PQQ or a salt thereof, as long as the effects of the present invention are not impaired.
- additives and ingredients can be selected according to the form of the composition and the like, and generally those that can be used for foods and drinks, pharmaceuticals, quasi-drugs, feeds and the like can be used.
- the composition of the present invention is a food or drink, a pharmaceutical product, a quasi-drug, a feed or the like, the production method thereof is not particularly limited and can be produced by a general method.
- composition of the present invention when used as a food or drink, one or more kinds of sesamin and PQQ or a salt thereof may contain components that can be used in the food or drink (for example, food materials, food additives used as necessary, etc.). ) Can be blended into various foods and drinks.
- Foods and drinks are not particularly limited, and examples thereof include general foods and drinks, health foods, health drinks, foods with functional claims, foods for specified health use, dietary supplements, foods and drinks for the sick, and the like.
- the above-mentioned health foods, foods with functional claims, foods for specified health use, dietary supplements, etc. are, for example, fine granules, tablets, granules, powders, capsules, chewables, dry syrups, syrups, liquids, beverages, fluids. It can be used as various formulations such as food.
- composition of the present invention is a pharmaceutical product or a quasi-drug
- a pharmacologically acceptable carrier for example, an additive added as necessary, etc. to one or more of sesamines and PQQ or a salt thereof, etc.
- Such carriers, additives and the like may be pharmacologically acceptable as long as they can be used in pharmaceutical products or quasi-drugs, for example, excipients, binders, disintegrants, lubricants, etc.
- antioxidants, colorants and the like can be mentioned.
- Examples of the administration (ingestion) form of the drug or quasi-drug include oral or parenteral (transdermal, transmucosal, intestinal, injection, etc.) administration forms.
- composition of the present invention is a drug or a quasi-drug
- it is preferably an oral drug or a quasi-drug.
- Dosage forms for oral administration include liquids, tablets, powders, fine granules, granules, sugar-coated tablets, capsules, suspensions, emulsions, chewables and the like.
- the drug may be a non-human veterinary drug.
- composition of the present invention When the composition of the present invention is used as a feed, one or more of sesamin and PQQ or a salt thereof may be added to the feed.
- the feed also contains feed additives. Examples of the feed include livestock feed used for cattle, pigs, chickens, sheep, horses and the like; small animal feed used for rabbits, rats, mice and the like; pet food used for dogs, cats, small birds and the like.
- the content of sesamin contained in the composition of the present invention is not particularly limited and can be set according to the form and the like.
- the total content of sesamines in the composition of the present invention is, for example, preferably 0.001% by weight or more, more preferably 0.01% by weight or more, still more preferably 0.05% by weight or more in the composition. , 10% by weight or less is preferable, and 5% by weight or less is more preferable.
- the total content of sesamin is preferably 0.001 to 10% by weight, more preferably 0.01 to 5% by weight, still more preferably 0.05 to 5% by weight in the composition.
- the content of PQQ or a salt thereof contained in the composition of the present invention is not particularly limited and can be set according to its form and the like.
- the content of PQQ or a salt thereof in the composition of the present invention is, for example, preferably 0.0001% by weight or more, more preferably 0.001% by weight or more, and further preferably 0.005% by weight or more in the composition. It is preferable, and it is preferably 20% by weight or less, and more preferably 10% by weight or less.
- the content of PQQ or a salt thereof is preferably 0.0001 to 20% by weight, more preferably 0.001 to 10% by weight, and 0.05 to 10% by weight in the composition in terms of PQQ. More preferred.
- the composition of the present invention is preferably taken orally (orally administered).
- the dose (which can also be referred to as ingestion) of the composition of the present invention is not particularly limited.
- the dose of the composition of the present invention is such that an effect of improving, suppressing or maintaining mitochondrial function, an effect of improving, suppressing or maintaining mitochondrial energy production ability, and / or an anti-fatigue effect can be obtained.
- it may be appropriately set according to the administration form, administration method, body weight of the subject, and the like.
- the total dose of sesamin is preferably 0.5 mg or more per 60 kg of body weight per day, more preferably 0.5 mg or more. It is 1 mg or more, more preferably 3 mg or more, preferably 200 mg or less, more preferably 100 mg or less, still more preferably 80 mg or less.
- the total dose of PQQ or a salt thereof is preferably 0.5 mg or more, more preferably 1 mg or more, still more preferably 3 mg or more, and preferably 200 mg or less, more preferably 200 kg or less per day in terms of PQQ. Is 100 mg or less, more preferably 80 mg or less.
- the total dose of sesamin is preferably 0.5 to 200 mg, more preferably 1 to 100 mg, still more preferably 3 to 80 mg per 60 kg of body weight per day for humans (adults).
- the total dose of PQQ or a salt thereof is, in terms of PQQ, for humans (adults), preferably 0.5 to 400 mg, more preferably 1 to 200 mg, still more preferably 3 to 3 to 60 kg of body weight per day. It is 160 mg. It is preferable to ingest or administer the above amount once or more a day, for example, once a day or several times (for example, 2 to 3 times). In one embodiment, it is preferable that the above amounts of sesamin and PQQ or a salt thereof are orally ingested or administered to humans.
- composition of the present invention is preferably continuously ingested or administered. It is expected that the above effects will be enhanced by continuous ingestion or administration of sesamin and PQQ or a salt thereof.
- the composition of the present invention is preferably ingested or administered continuously for 1 week or longer, more preferably 4 weeks or longer, further preferably 8 weeks or longer, and particularly preferably 12 weeks or longer. preferable.
- Pets are so-called companion animals such as dogs, cats, marmosets, small birds and hamsters, and companion animals, and experimental animals are mice, rats, guinea pigs, beagle dogs, miniature pigs, red-tailed monkeys and crab monkeys, etc. And represents animals used for research in fields such as pharmacy.
- the administration target of the composition of the present invention is preferably a human or a non-human mammal, and more preferably a human.
- the subject to be administered is a subject who needs or desires improvement, suppression or maintenance of mitochondrial function, a subject who needs or desires improvement, suppression or maintenance of mitochondrial energy production ability, or anti. Examples include objects that require or desire a fatigue effect.
- mitochondrial function decreases with aging.
- middle-aged and elderly people are preferable as the target of the composition of the present invention.
- the composition of the present invention may be an anti-fatigue composition for middle-aged and elderly people (preferably for elderly people).
- the composition of the present invention is used for a healthy person for the purpose of improving, suppressing or maintaining mitochondrial function, improving, suppressing or maintaining mitochondrial energy production ability, and anti-fatigue effect. You can also do it.
- the composition of the present invention comprises "reducing fatigue”, “less likely to feel fatigue”, “maintaining vitality”, “improving vitality”, “helping energy production” and “full of energy”.
- One or more indications selected from the group may be attached.
- a feeling of fatigue and a decrease in vitality may be easily felt with aging.
- Energy production may be that produced by cells or mitochondria.
- the composition of the present invention is preferably a food or drink with the above indication.
- the above display may be a display to the effect that it is used to obtain the above function.
- the present invention also includes the following methods and uses.
- the above method may be a therapeutic method or a non-therapeutic method.
- the use may be a therapeutic method or use, or may be a non-therapeutic method or use.
- the present invention also includes the use of one or more of sesamin and PQQ or salts thereof for producing the compositions of the present invention.
- the present invention comprises one or more sesamin species for producing a composition for improving, suppressing or maintaining mitochondrial function and / or mitochondrial energy production ability, and PQQ or a salt thereof. It may be the use of the composition containing. Further, the present invention may use one or more kinds of sesamin for producing an anti-fatigue composition, and a composition containing PQQ or a salt thereof.
- sesamin and PQQ or salts thereof are the same as the compositions of the present invention described above.
- one or more kinds of sesamin one kind of compound of sesamin may be used, and two or more kinds may be used.
- once or more a day for example, once to several times a day (for example, 2 to 3 times), one or more kinds of sesamin, and PQQ or a salt thereof are administered (ingested) to the subject. ) Is preferable.
- the above use is preferably in humans or non-human mammals, more preferably in humans.
- one or more kinds of sesamin in an amount (which can be said to be an effective amount) capable of obtaining a desired action, and PQQ or a salt thereof may be used.
- the preferred doses of sesamin and PQQ or a salt thereof, the subject of administration, and the like are the same as those of the composition of the present invention described above.
- Sesamin and PQQ or a salt thereof may be administered as they are, or may be administered as a composition containing them.
- the composition of the present invention described above may be used.
- a composition containing sesamines and a composition containing PQQ or a salt thereof are individually prepared, and they are taken at almost the same time, or after taking one of the compositions, while the effect is maintained. If the other composition is taken, the effect of one or more of the sesamines intended by the present invention and the composition containing PQQ or a salt thereof (improvement of mitochondrial function, suppression or maintenance of decrease, mitochondrial energy) An effect of improving the productivity, suppressing or maintaining the decrease, and / or enhancing the anti-fatigue effect) can be obtained. Therefore, a kit or the like containing a composition containing sesamin and a composition containing PQQ or a salt thereof is also included in the scope of the composition of the present invention.
- SE sesamin / episesamin mixture
- PQQ PQQ / 2Na evaluation test of mitochondrial function>
- the medium supplemented with the sesamin / episesamin mixture and PQQ was removed, and the cells in the wells were treated with the medium supplemented with H 2 O 2 (800 ⁇ M) for 2 hours. Then, the medium was replaced with an analytical medium, and the oxygen consumption rate was analyzed with an analytical instrument (XF analyzer, Agilent, Inc.). After completion of the analysis, the nuclei were stained with Hoechst He, the cells were photographed with a fluorescence microscope BZ-x (KEYENCE Co., Ltd.), and the number of cells was counted by image analysis. The amount of ATP produced was defined as the amount of decrease in oxygen consumption rate due to ATP synthase inhibition (oligomycin). The results obtained are shown in Table 1 and FIG.
- ⁇ Reference example 1 Evaluation test of mitochondrial function in the untreated group> To examine mitochondrial function, 5.5 ⁇ 10 3 cells / well TIG-3 cells were seeded on a special plate and cultured at 37 ° C. and CO 2 (5%) for 24 hours. After 24 hours of culturing, the composition containing the sesamine / episesamine mixture and PQQ was added to the medium, and the cells in the cells were treated with H 2 O 2 (800 ⁇ M) -added medium for 2 hours for an additional 26 hours. The oxygen consumption rate in Reference Example 1 was analyzed and the number of cells was counted in the same manner as in Example 1 except that the cells were cultured. In addition, the amount of ATP produced was measured. The results obtained are shown in Table 1.
- Comparative Example 1 Evaluation test of mitochondrial function in H 2 O 2 treatment group> To examine mitochondrial function, 5.5 ⁇ 10 3 cells / well TIG-3 cells were seeded on a special plate and cultured at 37 ° C. and CO 2 (5%) for 24 hours. After 24 hours of culturing, the oxygen consumption rate in Comparative Example 1 was analyzed in the same manner as in Example 1 except that the composition containing the sesamine / episesamine mixture and PQQ was further cultured for 24 hours without addition to the medium. Then, the number of cells was counted. In addition, the amount of ATP produced was measured. The results obtained are shown in Table 1.
- the "actual measurement value” (pmol / min / 10 3 cells) shows the amount of ATP produced (the amount of decrease in oxygen consumption rate due to ATP synthase inhibition) obtained above.
- the “recovery rate (%) from Comparative Example 1” is a value obtained by dividing the measured values of Examples and Comparative Examples by the measured values of Comparative Example 1 and multiplying by 100. The higher the recovery rate, the higher the amount of ATP produced.
- FIG. 1 shows the recovery rate (%) (recovery rate with respect to Comparative Example 1) obtained for Examples and Comparative Examples.
- SE represents a sesamin / episesamin mixture.
- FIG. 1 represents a sesamin / episesamin mixture.
- the amount of ATP produced decreased by 48.1% with respect to the control group (Reference Example 1) by the 800 ⁇ M H 2 O 2 treatment according to Comparative Example 1. Further, in the PQQ (10 nM) treatment according to Comparative Example 5 , the ATP production amount decreased by 5.5% as compared with the H 2 O 2 treatment group according to Comparative Example 1, but the PQQ (PQQ) according to Comparative Examples 6 to 9 ( In the 30 nM, 100 nM, 300 nM, 1 ⁇ M) treatment, 1.1%, 4.6%, 15.3%, and 17.8% were added to the H 2 O 2 treatment group according to Comparative Example 1, respectively. The amount of ATP produced increased in a dose-dependent manner with respect to PQQ.
- the ATP production amount did not increase additively, but that the composition containing the sesamine / episesamine mixture and PQQ synergistically increased the ATP production amount. That is, it was confirmed that the composition containing the sesamin / episesamin mixture and PQQ exerts an effect at a low dose because it shows a synergistic effect by containing both. It was also confirmed that the composition containing the sesamin / episesamin mixture and PQQ also showed a synergistic effect on suppressing the decrease in ATP production.
- the sesamin / episesamin mixture and PQQ show a synergistic effect of suppressing the decrease in ATP production.
- a composition containing a kind of sesamin and PQQ or a salt thereof can improve, suppress or maintain mitochondrial function, and improve, suppress or maintain mitochondrial energy production ability. be able to. As a result, an anti-fatigue effect is produced.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Botany (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
エネルギー産生の大部分は、細胞内小器官の一つであるミトコンドリア内で行われる。食事から摂取された栄養源である糖、脂質、アミノ酸などが、解糖系、ペントースリン酸経路、クエン酸回路で代謝され、NADH(ニコチンアミドアデニンジヌクレオチド)に変換される。次いで、NADHの電子がミトコンドリア呼吸鎖タンパク質(電子伝達系)に受け渡され、ATP(アデノシン三リン酸)の形でエネルギーを産生する。
ATP産生量が低下すると、代謝能低下による肥満、糖尿病発症リスク増加、筋力の低下、疲労増加、無気力・集中力の低下、うつ病などさまざまな問題が引き起こされることが知られている。
ミトコンドリアの機能低下は、加齢や酸化ストレスにより引き起こされ、ATP産生量が低下することが知られている(非特許文献1、4)。
〔1〕セサミン類の1種以上、及び、ピロロキノリンキノン(PQQ)又はその塩を含有する組成物。
〔2〕セサミン類の1種以上が、セサミン及び/又はエピセサミンである上記〔1〕に記載の組成物。
〔3〕セサミン類に対するPQQ又はその塩の重量比(PQQ又はその塩/セサミン類)がPQQ換算で、0.01~100である上記〔1〕又は〔2〕に記載の組成物。
〔4〕ミトコンドリア機能を向上、低下抑制又は維持させる上記〔1〕~〔3〕のいずれか一つに記載の組成物。
〔5〕ミトコンドリアのエネルギー産生能を向上、低下抑制又は維持させる上記〔1〕~〔4〕のいずれか一つに記載の組成物。
〔6〕活力の向上、低下抑制又は維持のために使用される上記〔1〕~〔5〕のいずれか一つに記載の組成物。
〔7〕抗疲労用組成物である上記〔1〕~〔6〕のいずれか一つに記載の組成物。
〔8〕経口用組成物である上記〔1〕~〔7〕のいずれか一つに記載の組成物。
〔9〕飲食品である上記〔1〕~〔8〕のいずれか一つに記載の組成物。
〔10〕「疲労感の軽減」、「疲労を感じにくい」、「活力の維持」、「活力の向上」、「エネルギー産生を助ける」及び「エネルギーに溢れている」からなる群から選択される1以上の表示を付した上記〔1〕~〔9〕のいずれか一つに記載の組成物。
〔11〕セサミン類の1種以上、及び、ピロロキノリンキノン(PQQ)又はその塩を投与する、ミトコンドリア機能及び/又はミトコンドリアのエネルギー産生能を向上、低下抑制又は維持する方法。
〔12〕セサミン類の1種以上、及び、ピロロキノリンキノン(PQQ)又はその塩を投与する、疲労の抑制、軽減又は改善方法。
〔13〕ミトコンドリア機能及び/又はミトコンドリアのエネルギー産生能の向上、低下抑制又は維持のための、セサミン類の1種以上、及び、ピロロキノリンキノン(PQQ)又はその塩の使用。
〔14〕抗疲労のためのセサミン類の1種以上、及び、ピロロキノリンキノン(PQQ)又はその塩の使用。
セサミン類は、胡麻の主要なリグナン類化合物の一種で、胡麻中に0.5~1.0重量%程度含まれている。人工的に合成された化合物の長期的摂取は、予期せぬ副作用等の観点から好ましくない一方で、安全性の担保されたセサミン類は、長期的摂取に最適である。
本発明において、セサミン類とは、セサミン及びその類縁体を含む化合物の総称である。セサミンは、ゴマに含まれる主要なリグナン化合物の一種である。セサミン類縁体としては、エピセサミンの他、例えば特開平4-9331号公報に記載されたジオキサビシクロ[3.3.0]オクタン誘導体が挙げられる。セサミン類の1種以上として、これらの化合物の1種を単独で用いてもよく、2種以上を用いてもよい。セサミン類の具体例としては、セサミン、エピセサミン、セサミノール、エピセサミノール、セサモール、セサモリン等を例示でき、これらの立体異性体又はラセミ体を単独で、または混合して使用することができる。また、セサミン類の代謝物(例えば、特開2001-139579号公報に記載)も、本発明の効果を示す限り、本発明のセサミン類に含まれるセサミン類縁体であり、本発明に使用することができる。本発明においては、セサミン類の1種以上として、セサミン及び/又はエピセサミンを好適に用いることができ、セサミン及びエピセサミンをより好適に用いることができる。セサミン及びエピセサミンを用いる場合、これらの比率は特に限定されないが、例えば、セサミン:エピセサミン(重量比)が1:0.1~1:9が好ましく、1:0.3~1:3がより好ましく、1:0.5~1:2がさらに好ましい。
本発明の組成物は、ピロロキノリンキノン(PQQ)又はその塩を含む。
PQQは、酸化還元補酵素である。PQQ又はその塩は、植物、細菌、動物等の種々の生物体内に存在するため、種々の生物から抽出して調製することができる。PQQ又はその塩は、市販品を使用することもできる。本発明においては、本発明の効果を奏することになる限り、PQQ又はその塩を豊富に含む植物由来原料等を本発明の組成物に含有させてもよい。
PQQの塩における塩の置換数は、1~3であり、好ましくは2である。PQQの塩として、PQQの二ナトリウム塩が好ましい。
本発明の組成物は、上記セサミン類と上記PQQ又はその塩とを含有する。本発明の組成物において、ミトコンドリア機能及び/又はミトコンドリアのエネルギー産生能の向上作用、低下抑制作用又は維持作用を相乗的に高める観点から、セサミン類に対するPQQの重量比(PQQ/セサミン類)がPQQ換算で、0.01~100であることが好ましく、0.1~10であることがより好ましく、0.2~5であることがさらに好ましい。ミトコンドリア機能及び/又はミトコンドリアのエネルギー産生能の向上作用、低下抑制作用又は維持作用を高めることにより、抗疲労効果を奏するため、本発明の組成物において、セサミン類とPQQ又はその塩との重量比を上記特定の範囲とすることは抗疲労作用の観点からも好ましい。
なお、本明細書において、PQQ又はその塩の量を示す際は、ピロロキノリンキノン(PQQ)量に換算した値を用いる。
本発明の抗疲労用組成物は、身体疲労及び/又は精神疲労を抑制、軽減又は改善するため、身体的疲労感及び/又は精神的疲労感を抑制、軽減又は改善するため等に使用することができ、なかでも、身体疲労を抑制、軽減又は改善するため、身体的疲労感を抑制、軽減又は改善するために好ましく使用することができる。
本発明の組成物は、一例として、剤の形態で提供することができるが、本形態に限定されるものではない。当該剤をそのまま組成物として、又は、当該剤を含む組成物として提供することもできる。本発明の一態様として、本発明の抗疲労用組成物は抗疲労剤ということもできる。
本発明の組成物は、経口用組成物、非経口用組成物のいずれであってもよいが、好ましくは経口用組成物である。経口用組成物としては、飲食品、経口用の医薬品、医薬部外品、飼料が挙げられ、好ましくは飲食品又は経口用医薬品であり、より好ましくは飲食品である。
本発明の組成物中のセサミン類の総含有量は、例えば、該組成物中に0.001重量%以上が好ましく、0.01重量%以上がより好ましく、0.05重量%以上がさらに好ましく、また、10重量%以下が好ましく、5重量%以下がより好ましい。
一態様において、セサミン類の総含有量は、組成物中に0.001~10重量%が好ましく、0.01~5重量%がより好ましく、0.05~5重量%がさらに好ましい。
本発明の組成物中のPQQ又はその塩の含有量は、例えば、該組成物中に0.0001重量%以上が好ましく、0.001重量%以上がより好ましく、0.005重量%以上がさらに好ましく、また、20重量%以下が好ましく、10重量%以下がより好ましい。
一態様において、PQQ又はその塩の含有量は、PQQ換算で、組成物中に0.0001~20重量%が好ましく、0.001~10重量%がより好ましく、0.05~10重量%がさらに好ましい。
一態様において、セサミン類の総投与量は、ヒト(成人)であれば、1日当たり体重60kg当たり、好ましくは0.5~200mg、より好ましくは1~100mg、さらに好ましくは3~80mgである。また、PQQ又はその塩の総投与量は、PQQ換算で、ヒト(成人)であれば、1日当たり体重60kg当たり、好ましくは0.5~400mg、より好ましくは1~200mg、さらに好ましくは3~160mgである。
上記量を、1日1回以上、例えば、1日1回又は数回(例えば2~3回)に分けて、摂取させる又は投与することが好ましい。
一態様においては、上記量のセサミン類とPQQ又はその塩とを、ヒトに経口で摂取させる又は投与することが好ましい。
一態様において、本発明の組成物は、ヒトに、体重60kgあたり、1日あたり上記量のセサミン類とPQQ又はその塩とを摂取させる又は投与するために使用することができる。
なお、セサミン類の上記総投与量について、セサミン類の化合物を2種以上使用する場合は、これらの合計量である。
一態様においては、セサミン及び/又はエピセサミンを、セサミン及びエピセサミンの総投与量として1日当たり体重60kg当たり、好ましくは0.5~200mg、より好ましくは1~100mg、さらに好ましくは3~80mg、ヒト(成人)に経口で摂取させる又は投与することが好ましい。
一態様において、投与対象として、ミトコンドリア機能の向上、低下抑制又は維持を必要とする又は希望する対象や、ミトコンドリアのエネルギー産生能の向上、低下抑制又は維持を必要とする又は希望する対象や、抗疲労効果を必要とする又は希望する対象などが挙げられる。また、上記のように加齢によりミトコンドリア機能が低下することが知られている。一態様において本発明の組成物の対象として中高年者が好ましい。本発明の組成物は、中高年者用(好ましくは高齢者用)の抗疲労用組成物であってよい。また、本発明の組成物は、例えば、ミトコンドリア機能の向上、低下抑制又は維持や、ミトコンドリアのエネルギー産生能の向上、低下抑制又は維持や、抗疲労効果を目的として、健常者に対して使用することもできる。
セサミン類の1種以上、及び、ピロロキノリンキノン(PQQ)又はその塩を投与する、ミトコンドリア機能及び/又はミトコンドリアのエネルギー産生能を向上、低下抑制又は維持する方法。
セサミン類の1種以上、及び、ピロロキノリンキノン(PQQ)又はその塩を投与する、疲労の抑制、軽減又は改善方法。
ミトコンドリア機能及び/又はミトコンドリアのエネルギー産生能の向上、低下抑制又は維持のためのセサミン類の1種以上、及び、ピロロキノリンキノン(PQQ)又はその塩の使用。
抗疲労のためのセサミン類の1種以上、及び、ピロロキノリンキノン(PQQ)又はその塩の使用。
上記方法は、治療的な方法であってもよく、非治療的な方法であってもよい。上記使用は、治療的な方法又は使用であってもよく、非治療的な方法又は使用であってもよい。
セサミン類の1種以上、及び、PQQ又はその塩を投与することにより、ミトコンドリア機能及び/又はミトコンドリアのエネルギー産生能の向上、低下抑制又は維持が可能となり、抗疲労が可能となる。
具体的に、本発明は、ミトコンドリア機能及び/又はミトコンドリアのエネルギー産生能を、向上、低下抑制又は維持するための組成物を製造するためのセサミン類の1種以上、及び、PQQ又はその塩を含む組成物の使用であってもよい。
また、本発明は、抗疲労用組成物を製造するためのセサミン類の1種以上、及び、PQQ又はその塩を含む組成物の使用であってもよい。
ミトコンドリア機能を調べるため、5.5×103cells/wellのTIG-3細胞を専用プレートに播き、37℃、CO2(5%)の条件で24時間培養した。培養24時間後に、セサミン・エピセサミン混合物及びPQQを含む各組成物を、それぞれ下記表1に記載の濃度でウェル中の培地に添加し、24時間培養した。その後、セサミン・エピセサミン混合物及びPQQを添加した培地を取り除き、ウェル中の細胞を、H2O2(800μM)添加培地で2時間処理した。その後、解析培地に交換し、分析機器(XF analyzer、Agilent株式会社)にて酸素消費速度を分析した。分析終了後、ヘキストHeで核を染色し、細胞を蛍光顕微鏡BZ-x(株式会社キーエンス)で撮影し、画像解析にて細胞数のカウントを行った。ATP産生量は、ATPシンターゼ阻害(オリゴマイシン)による酸素消費速度減少量とした。得られた結果を表1及び図1に示す。
ミトコンドリア機能を調べるため、5.5×103cells/wellのTIG-3細胞を専用プレートに播き、37℃、CO2(5%)の条件で24時間培養した。培養24時間後に、セサミン・エピセサミン混合物及びPQQを含む組成物の培地への添加、及び、セル中の細胞のH2O2(800μM)添加培地で2時間処理を行うことなく、さらに、26時間培養した以外は、実施例1と同様にして、参考例1における酸素消費速度を分析し、細胞数をカウントした。また、ATP産生量を測定した。得られた結果を表1に示す。
ミトコンドリア機能を調べるため、5.5×103cells/wellのTIG-3細胞を専用プレートに播き、37℃、CO2(5%)の条件で24時間培養した。培養24時間後に、セサミン・エピセサミン混合物及びPQQを含む組成物の培地への添加を行うことなく、さらに24時間培養した以外は、実施例1と同様にして、比較例1における酸素消費速度を分析し、細胞数をカウントした。また、ATP産生量を測定した。得られた結果を表1に示す。
ミトコンドリア機能を調べるため、5.5×103cells/wellのTIG-3細胞を専用プレートに播き、37℃、CO2(5%)の条件で24時間培養した。培養24時間後に、セサミン・エピセサミン混合物又はPQQをそれぞれ下記表1に記載の濃度でウェル中の培地に添加し、24時間培養した。これ以外は、上記実施例1と同様にして比較例2~9における酸素消費速度を分析し、細胞数をカウントした。また、ATP産生量を測定した。得られた結果を表1に示す。
「比較例1からの回復率(%)」は、実施例及び比較例の実測値を比較例1の実測値で除して100を乗じた値である。回復率が高いほど、ATP産生量が多いことを意味する。図1に、実施例及び比較例について求めた回復率(%)(比較例1に対する回復率)を示す。図1中、SEはセサミン・エピセサミン混合物を示す。
図1において、「比較例6+比較例2」は、比較例2の回復率と比較例6の回復率の和であり、「比較例7+比較例2」は、比較例2の回復率と比較例7の回復率の和であり、「比較例8+比較例2」は、比較例2の回復率と比較例8の回復率の和であり、「比較例9+比較例2」は、比較例2の回復率と比較例9の回復率の和である。「比較例6+比較例2」、「比較例7+比較例2」、「比較例8+比較例2」及び「比較例9+比較例2」は、セサミン類単独(比較例2)、及び、PQQ単独(比較例6、7、8又は9)の場合の回復率から予測される、セサミン類及びPQQを組み合わせた場合の回復率を示す。
表1のように、ATP産生量は、コントロール群(参考例1)に対して比較例1に係る800μMのH2O2処理で、48.1%低下した。また、比較例5に係るPQQ(10nM)処理では、比較例1に係るH2O2処理群に対して、ATP産生量は5.5%減少したが、比較例6~9に係るPQQ(30nM、100nM、300nM、1μM)処理では、それぞれ比較例1に係るH2O2処理群に対して、1.1%、4.6%、15.3%、17.8%と、添加したPQQに対し用量依存的にATP産生量が増加した。以上より、PQQ処理によるATP産生量低下抑制効果を確認した。また、比較例2~4に係るセサミン・エピセサミン混合物(100nM、300nM、1μM)処理では、それぞれ比較例1に係るH2O2処理群に対して、3.8%、8.0%、8.5%と、添加したセサミン・エピセサミン混合物に対し用量依存的にATP産生量が増加した。以上より、セサミン・エピセサミン混合物処理によるATP産生量低下抑制効果を確認した。次に、実施例1~5にかかる、セサミン・エピセサミン混合物(100nM)及び、PQQ(10nM、30nM、100nM、300nM、1μM)を各濃度で含む組成物による処理では、比較例1に係るH2O2処理群に対して、6.7%、9.1%、12.6%、27.8%、25.3%ATP産生量が増加した。これは、図1に示すように、セサミン・エピセサミン混合物単独のATP産生量増加率及びPQQ単独のATP産生量増加率の合算値よりも大きい値であり、単に、PQQ及びセサミン・エピセサミン混合物に対し相加的にATP産生量が増加したのではなく、セサミン・エピセサミン混合物とPQQとを含む組成物により、相乗的にATP産生量が増加したことを確認した。すなわち、セサミン・エピセサミン混合物とPQQとを含む組成物は、両者を含むことによる相乗的な効果を示すため、低用量で効果を発揮することを確認した。
また、セサミン・エピセサミン混合物とPQQとを含む組成物は、ATP産生量低下抑制についても相乗的な効果を示すことを確認した。
Claims (14)
- セサミン類の1種以上、及び、ピロロキノリンキノン(PQQ)又はその塩を含有する組成物。
- セサミン類の1種以上が、セサミン及び/又はエピセサミンである請求項1に記載の組成物。
- セサミン類に対するPQQ又はその塩の重量比(PQQ又はその塩/セサミン類)がPQQ換算で、0.01~100である請求項1又は2に記載の組成物。
- ミトコンドリア機能を向上、低下抑制又は維持させる請求項1~3のいずれか一項に記載の組成物。
- ミトコンドリアのエネルギー産生能を向上、低下抑制又は維持させる請求項1~4のいずれか一項に記載の組成物。
- 活力の向上、低下抑制又は維持のために使用される請求項1~5のいずれか一項に記載の組成物。
- 抗疲労用組成物である請求項1~6のいずれか一項に記載の組成物。
- 経口用組成物である請求項1~7のいずれか一項に記載の組成物。
- 飲食品である請求項1~8のいずれか一項に記載の組成物。
- 「疲労感の軽減」、「疲労を感じにくい」、「活力の維持」、「活力の向上」、「エネルギー産生を助ける」及び「エネルギーに溢れている」からなる群から選択される1以上の表示を付した請求項1~9のいずれか一項に記載の組成物。
- セサミン類の1種以上、及び、ピロロキノリンキノン(PQQ)又はその塩を投与する、ミトコンドリア機能及び/又はミトコンドリアのエネルギー産生能を向上、低下抑制又は維持する方法。
- セサミン類の1種以上、及び、ピロロキノリンキノン(PQQ)又はその塩を投与する、疲労の抑制、軽減又は改善方法。
- ミトコンドリア機能及び/又はミトコンドリアのエネルギー産生能の向上、低下抑制又は維持のための、セサミン類の1種以上、及び、ピロロキノリンキノン(PQQ)又はその塩の使用。
- 抗疲労のためのセサミン類の1種以上、及び、ピロロキノリンキノン(PQQ)又はその塩の使用。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021567395A JP7536044B2 (ja) | 2019-12-27 | 2020-12-18 | セサミン類及びpqqを含有する組成物 |
CA3166181A CA3166181A1 (en) | 2019-12-27 | 2020-12-18 | Composition containing sesamin and pqq |
AU2020413847A AU2020413847A1 (en) | 2019-12-27 | 2020-12-18 | Composition containing sesamin and PQQ |
KR1020227025689A KR20220122693A (ko) | 2019-12-27 | 2020-12-18 | 세사민류 및 pqq를 함유하는 조성물 |
US17/788,514 US20230040209A1 (en) | 2019-12-27 | 2020-12-18 | Composition containing sesamin and pqq |
CN202080090618.5A CN114901083A (zh) | 2019-12-27 | 2020-12-18 | 含有芝麻素类及pqq的组合物 |
EP20904549.1A EP4082612A1 (en) | 2019-12-27 | 2020-12-18 | Composition containing sesamin and pqq |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019-238782 | 2019-12-27 | ||
JP2019238782 | 2019-12-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021132077A1 true WO2021132077A1 (ja) | 2021-07-01 |
Family
ID=76574645
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2020/047425 WO2021132077A1 (ja) | 2019-12-27 | 2020-12-18 | セサミン類及びpqqを含有する組成物 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20230040209A1 (ja) |
EP (1) | EP4082612A1 (ja) |
JP (1) | JP7536044B2 (ja) |
KR (1) | KR20220122693A (ja) |
CN (1) | CN114901083A (ja) |
AU (1) | AU2020413847A1 (ja) |
CA (1) | CA3166181A1 (ja) |
TW (1) | TW202135801A (ja) |
WO (1) | WO2021132077A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024095303A1 (ja) * | 2022-10-31 | 2024-05-10 | サントリーホールディングス株式会社 | エネルギー産生の向上、低下抑制又は維持用組成物 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117426507B (zh) * | 2023-11-22 | 2024-05-03 | 广州能量生物科技有限公司 | 一种保护线粒体和溶血栓的保健食品及其制备方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH049331A (ja) | 1990-04-03 | 1992-01-14 | Suntory Ltd | 肝機能改善剤 |
JP2001139579A (ja) | 1999-11-18 | 2001-05-22 | Suntory Ltd | リグナン系抗酸化剤及びその製造法 |
WO2006025247A1 (ja) * | 2004-08-30 | 2006-03-09 | Kaneka Corporation | ミトコンドリア賦活剤 |
JP2009215170A (ja) | 2008-03-06 | 2009-09-24 | Fuji Chem Ind Co Ltd | エネルギー産生代謝向上組成物 |
JP2012019739A (ja) * | 2010-07-15 | 2012-02-02 | Mitsubishi Gas Chemical Co Inc | ストレス低減食品 |
JP2015096494A (ja) * | 2013-10-07 | 2015-05-21 | かどや製油株式会社 | 生体内酸化還元状態改善剤 |
WO2018079717A1 (ja) | 2016-10-31 | 2018-05-03 | 株式会社 資生堂 | 水中油型皮膚外用組成物 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2008062559A1 (ja) * | 2006-11-22 | 2010-03-04 | 旭化成ファーマ株式会社 | 栄養補助食品、抗疲労作用剤又は持久力増強剤、機能性食品又は化粧料 |
US9609884B2 (en) * | 2007-03-15 | 2017-04-04 | Suntory Holdings Limited | Anti-fatigue agent |
AU2008301694B2 (en) * | 2007-09-19 | 2013-07-18 | Suntory Holdings Limited | Compositions Containing Sesamin-Class Compound(s) and Arachidonic Acid Class Compound(s) |
US20170312200A1 (en) * | 2014-10-29 | 2017-11-02 | Showa Denko K.K. | An agent for improving mitochondrial function |
CN108292366B (zh) | 2015-09-10 | 2022-03-18 | 美基蒂克艾尔有限公司 | 在内窥镜手术中检测可疑组织区域的系统和方法 |
JP6682073B2 (ja) * | 2016-02-12 | 2020-04-15 | 株式会社東洋新薬 | 肝機能改善剤 |
CN105995350A (zh) * | 2016-06-15 | 2016-10-12 | 湖北华蒜豆生物科技有限公司 | 一种华蒜豆饮料及其制作方法 |
US10878219B2 (en) | 2016-07-21 | 2020-12-29 | Siemens Healthcare Gmbh | Method and system for artificial intelligence based medical image segmentation |
JP7007828B2 (ja) * | 2017-07-28 | 2022-02-10 | 小林製薬株式会社 | ミトコンドリア機能向上剤 |
-
2020
- 2020-12-18 US US17/788,514 patent/US20230040209A1/en active Pending
- 2020-12-18 CA CA3166181A patent/CA3166181A1/en active Pending
- 2020-12-18 EP EP20904549.1A patent/EP4082612A1/en not_active Withdrawn
- 2020-12-18 JP JP2021567395A patent/JP7536044B2/ja active Active
- 2020-12-18 WO PCT/JP2020/047425 patent/WO2021132077A1/ja unknown
- 2020-12-18 KR KR1020227025689A patent/KR20220122693A/ko unknown
- 2020-12-18 AU AU2020413847A patent/AU2020413847A1/en active Pending
- 2020-12-18 CN CN202080090618.5A patent/CN114901083A/zh active Pending
- 2020-12-22 TW TW109145478A patent/TW202135801A/zh unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH049331A (ja) | 1990-04-03 | 1992-01-14 | Suntory Ltd | 肝機能改善剤 |
JP2001139579A (ja) | 1999-11-18 | 2001-05-22 | Suntory Ltd | リグナン系抗酸化剤及びその製造法 |
WO2006025247A1 (ja) * | 2004-08-30 | 2006-03-09 | Kaneka Corporation | ミトコンドリア賦活剤 |
JP2009215170A (ja) | 2008-03-06 | 2009-09-24 | Fuji Chem Ind Co Ltd | エネルギー産生代謝向上組成物 |
JP2012019739A (ja) * | 2010-07-15 | 2012-02-02 | Mitsubishi Gas Chemical Co Inc | ストレス低減食品 |
JP2015096494A (ja) * | 2013-10-07 | 2015-05-21 | かどや製油株式会社 | 生体内酸化還元状態改善剤 |
WO2018079717A1 (ja) | 2016-10-31 | 2018-05-03 | 株式会社 資生堂 | 水中油型皮膚外用組成物 |
Non-Patent Citations (13)
Title |
---|
ANONYMOUS: "Chinese style natto", COOKPAD, 19 April 2011 (2011-04-19), pages 1 - 3, XP055924325, Retrieved from the Internet <URL:https://cookpad.com/recipe/1411011> [retrieved on 20220524] * |
ANONYMOUS: "Do you really need that supplement?", 29 April 2015 (2015-04-29), pages 1 - 3, XP055924329, Retrieved from the Internet <URL:https://recipe.seikatsuclub.coop/news_story_detail.html?NTC=0000150049> [retrieved on 20210118] * |
ANONYMOUS: "For people who suffer from Fatique ", JP, pages 1 - 2, XP009536348, Retrieved from the Internet <URL:https://web.archive.org/web/2012125160206/http://mcm-www.jwu.ac.jp/~maruyama/onayami-hirou2.html> [retrieved on 20210119] * |
ANONYMOUS: "It's really amazing !! Natto nutrients", 24 May 2016 (2016-05-24), pages 1 - 6, XP055924326, Retrieved from the Internet <URL:https://web.archive.org/web/20160524083114/http://www.yamadafoods.co.jp/library/nutrient/> [retrieved on 20220524] * |
ANONYMOUS: "PQQ is one of our familiar foods, including fermented foods, vegetables and drinks!", 8 March 2015 (2015-03-08), pages 1 - 3, XP055924332, Retrieved from the Internet <URL:https://web.archive.org/web/20150308115005/http://www.mgc.co.jp/seihin/h/pqq/food> [retrieved on 20210118] * |
BEROZA ET AL., J. AM. CHEM. SOC., vol. 78, 1956, pages 1242 |
CHOWANADISAI, WINYOO ET AL.: "Pyrroloquinoline quinone stimulates mitochondrial biogenesis through cAMP response element-binding protein phosphorylation and increased PGC-la expression", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 285, no. 1, 2010, pages 142 - 152, XP055529282, DOI: 10.1074/jbc.M109.030130 |
CONLEY, KEVIN E.SHARON A. JUBRIASPETER C. ESSELMAN: "Oxidative capacity and ageing in human muscle", THE JOURNAL OF PHYSIOLOGY, vol. 526, no. 1, 2000, pages 203 - 210 |
KUDRYAVTSEVA, ANNA V. ET AL.: "Mitochondrial dysfunction and oxidative stress in aging and cancer", ONCOTARGET, vol. 7, no. 29, 2016, pages 44879, XP055746384, DOI: 10.18632/oncotarget.9821 |
MAHARJAN, SUNITA ET AL.: "Mitochondrial impairment triggers cytosolic oxidative stress and cell death following proteasome inhibition", SCIENTIFIC REPORTS, vol. 4, 2014, pages 5896 |
See also references of EP4082612A1 |
TAKADA, SHINGO ET AL.: "Sesamin prevents decline in exercise capacity and impairment of skeletal muscle mitochondrial function in mice with high-fat diet-induced diabetes", EXPERIMENTAL PHYSIOLOGY, vol. 100, no. 11, 2015, pages 1319 - 1330 |
URATA, CHEM. PHARM. BULL. (TOKYO, vol. 56, no. 11, 2008, pages 1611 - 2 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024095303A1 (ja) * | 2022-10-31 | 2024-05-10 | サントリーホールディングス株式会社 | エネルギー産生の向上、低下抑制又は維持用組成物 |
Also Published As
Publication number | Publication date |
---|---|
CN114901083A (zh) | 2022-08-12 |
TW202135801A (zh) | 2021-10-01 |
KR20220122693A (ko) | 2022-09-02 |
US20230040209A1 (en) | 2023-02-09 |
AU2020413847A1 (en) | 2022-08-11 |
CA3166181A1 (en) | 2021-07-01 |
EP4082612A1 (en) | 2022-11-02 |
JPWO2021132077A1 (ja) | 2021-07-01 |
JP7536044B2 (ja) | 2024-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11969411B2 (en) | Administration of berberine metabolites | |
US6479069B1 (en) | Nutritional supplement for increased energy and stamina | |
JP5714227B2 (ja) | アンドログラホリドを有効成分とする抗疲労剤及び経口組成物 | |
US20200129463A1 (en) | Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans | |
TWI407963B (zh) | Contains the composition of riboflavin and sesamin | |
JPH06504259A (ja) | 高コレステロール血症および細胞過増殖性障害の予防および処置用処方および方法 | |
WO2021132077A1 (ja) | セサミン類及びpqqを含有する組成物 | |
CN102753183A (zh) | 运动功能改善剂 | |
WO2021230145A1 (ja) | ニコチンアミドアデニンジヌクレオチド(nad)濃度上昇剤 | |
WO2022071117A1 (ja) | 抗疲労用組成物及びエネルギー産生能の向上、低下抑制又は維持のための組成物 | |
JP2009107987A (ja) | 筋力向上剤 | |
WO2021230146A1 (ja) | Nr及び/又はnmnとセサミン類とを含有する組成物 | |
JP2018197277A (ja) | 脂質代謝促進剤 | |
JP2005082495A (ja) | 脳細胞保護のための組成物 | |
WO2024190669A1 (ja) | セサミン類化合物及びフェルラ酸又はその塩を含有する組成物 | |
JP6677775B2 (ja) | 筋肉増強剤 | |
WO2024095303A1 (ja) | エネルギー産生の向上、低下抑制又は維持用組成物 | |
TW202419084A (zh) | 可提高或抑制降低或維持能量產生之組成物 | |
US20220362188A1 (en) | Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans | |
US20220202789A1 (en) | Administration of berberine metabolites | |
WO2023223943A1 (ja) | 血管内皮機能改善用組成物 | |
CN113490422A (zh) | 用于抑制/减少体重增加的组合物 | |
JP2022146639A (ja) | Nmn等含有組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20904549 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021567395 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3166181 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 20227025689 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020904549 Country of ref document: EP Effective date: 20220727 |
|
ENP | Entry into the national phase |
Ref document number: 2020413847 Country of ref document: AU Date of ref document: 20201218 Kind code of ref document: A |